Atherectomy plus antirestenotic therapy for SFA lesions: evolving evidence for better patency rates in complex lesions

J Cardiovasc Surg (Torino). 2019 Apr;60(2):205-211. doi: 10.23736/S0021-9509.19.10844-0. Epub 2019 Jan 16.

Abstract

Within the last years, many new endovascular treatment modalities have been invented for treatment of peripheral arterial disease. To leave nothing behind and to keep options for future treatment are key issues of these new revascularization procedures. Drug coated balloon technology (DCB) is one key element in this strategy but there are still limitations for this revascularization technology. Especially calcium rich lesions and long lesions are still challenging in terms of treatment success and long-term patency. Treatment of both calcified and long lesions continues to be a clinical challenge for every interventionalists. Therefore, a treatment combination of debulking procedure using atherectomy plus antirestenotic therapy using DCB seems to be promising to treat complex lesions.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon* / adverse effects
  • Angioplasty, Balloon* / instrumentation
  • Atherectomy* / adverse effects
  • Cardiovascular Agents / administration & dosage
  • Coated Materials, Biocompatible
  • Constriction, Pathologic
  • Female
  • Femoral Artery / diagnostic imaging
  • Femoral Artery / physiopathology*
  • Humans
  • Male
  • Middle Aged
  • Peripheral Arterial Disease / diagnostic imaging
  • Peripheral Arterial Disease / physiopathology
  • Peripheral Arterial Disease / therapy*
  • Recurrence
  • Risk Factors
  • Treatment Outcome
  • Vascular Access Devices
  • Vascular Calcification / diagnostic imaging
  • Vascular Calcification / physiopathology
  • Vascular Calcification / therapy*
  • Vascular Patency*

Substances

  • Cardiovascular Agents
  • Coated Materials, Biocompatible